The World Health Organization predicts that by 2050, one-fifth of the world’s population will be older than 60 years, with roughly 115 million individuals affected by dementia.1 These numbers do not account for the additional 16% to 20% of elderly individuals who are estimated to experience mild cognitive impairment, which can begin years before clinical presentation.2 Despite this large public health concern, interventional strategies are limited, and timely identification of prodromal disease states requires improvement. To date, most therapies aim to protect or preserve at-risk neurons, and there are very few therapies that target the brain’s white matter, which makes up half of the brain and may be a critical site of prodromal disease.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Roseborough A, Hachinski V, Whitehead S. White Matter Degeneration—A Treatable Target? JAMA Neurol. 2020;77(7):793–794. doi:10.1001/jamaneurol.2020.0814
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: